Cargando…

Potential to Enhance the Prescribing of Generic Drugs in Patients with Mental Health Problems in Austria; Implications for the Future

Background: Scrutiny over pharmaceutical expenditure is increasing leading to multiple reforms. This includes Austria with measures to lower generic prices and enhance their utilization. However the situation for newer antidepressants and atypical antipsychotic medicines (AAPs) is different to PPIs,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Godman, Brian, Bucsics, Anna, Burkhardt, Thomas, Piessnegger, Jutta, Schmitzer, Manuela, Barbui, Corrado, Raschi, Emanuel, Bennie, Marion, Gustafsson, Lars L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538280/ https://www.ncbi.nlm.nih.gov/pubmed/23308071 http://dx.doi.org/10.3389/fphar.2012.00198

Ejemplares similares

Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications
por: Godman, Brian, et al.
Publicado: (2014)

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications
por: Godman, Brian, et al.
Publicado: (2014)

Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria
por: Kossmeier, Michael, et al.
Publicado: (2021)

Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe
por: Raschi, Emanuel, et al.
Publicado: (2013)

Different initiatives across Europe to enhance losartan utilization post generics: impact and implications
por: Moon, James C., et al.
Publicado: (2014)

Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications
por: Godman, Brian, et al.
Publicado: (2011)

Discounts and rebates granted to public payers for medicines in European countries
por: Vogler, Sabine, et al.
Publicado: (2012)

Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors
por: Raschi, Emanuel, et al.
Publicado: (2019)

Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs
por: Malmström, Rickard E., et al.
Publicado: (2013)

Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs
por: Godman, Brian, et al.
Publicado: (2014)

Behaviour change interventions to promote prescribing of generic drugs: a rapid evidence synthesis and systematic review
por: Moe-Byrne, Thirimon, et al.
Publicado: (2014)

Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario.
por: Garcia, Marina Morgado, et al.
Publicado: (2020)

Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future
por: de Bruijn, Winnie, et al.
Publicado: (2016)

Generic Medicine and Generic Prescribing in Nepal: An Implication for Policymakers
por: Shrestha, Rajeev, et al.
Publicado: (2022)

Introduction of managed entry agreements in Korea: Problem, policy, and politics
por: Kim, Hyungmin, et al.
Publicado: (2023)

Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2021)

The concept of: Generic drugs and patented drugs vs. brand name drugs and non-proprietary (generic) name drugs
por: Thakkar, Karan B., et al.
Publicado: (2013)

Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone(®)
por: Lipsky, Peter, et al.
Publicado: (2021)

Generic switching: Do future physicians in Jordan have enough knowledge and a positive attitude?
por: Al Zoubi, Sura, et al.
Publicado: (2022)

Prescribing generics: All in a name
por: Roy, Vandana, et al.
Publicado: (2018)

Does China’s competitive generic substitution policy deliver equivalent clinical outcomes? A pilot study with two generic formulations of olanzepine
por: Zhang, Chao, et al.
Publicado: (2023)

Use of recommended medications after myocardial infarction in Austria
por: Winkelmayer, Wolfgang C., et al.
Publicado: (2007)

Nocebo in Biosimilars and Generics in Neurology: A Systematic Review
por: Spanou, Ioanna, et al.
Publicado: (2019)

Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
por: Godman, Brian, et al.
Publicado: (2010)

Prescribing Behavior of General Practitioners for Generic Drugs
por: Tuncay, Berna, et al.
Publicado: (2020)

Does mental health staffing level affect antipsychotic prescribing? Analysis of Italian national statistics
por: Starace, Fabrizio, et al.
Publicado: (2018)

Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing
por: Moudallel, Souad, et al.
Publicado: (2018)

The Development and Validation of a Generic Instrument, QoDoS, for Assessing the Quality of Decision Making
por: Donelan, Ronan, et al.
Publicado: (2016)

New pricing models for generic medicines to ensure long-term sustainable competition in Europe
por: Francois, Clement, et al.
Publicado: (2023)

Can Prescribed Cannabinoids Substitute Cannabis?
por: Batalla, A.
Publicado: (2022)

Recommendation for a Pilot MCDA Tool to Support the Value-Based Purchasing of Generic Medicines in the UAE
por: Farghaly, Mohamed Naser, et al.
Publicado: (2021)

Poor implementation of the EU clinical trial regulation is a major threat for pragmatic trials in European countries
por: Ostuzzi, Giovanni, et al.
Publicado: (2020)

Research on prescribing cascades: a scoping review
por: Chen, Zhe, et al.
Publicado: (2023)

Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model
por: Narendrula, Aparna, et al.
Publicado: (2023)

Is it ethical to prescribe generic immunosuppressive drugs to renal transplant patients?
por: Allard, Julie, et al.
Publicado: (2014)

Understanding of Future Prescribers About Antimicrobial Resistance and Their Preparedness Towards Antimicrobial Stewardship Activities in Pakistan: Findings and Implications
por: Hayat, Khezar, et al.
Publicado: (2022)

Clinical and Financial Implications of Medicine Consumption Patterns at a Leading Referral Hospital in Kenya to Guide Future Planning of Care
por: Kivoto, Patrick M., et al.
Publicado: (2018)

Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care
por: Mardare, Ileana, et al.
Publicado: (2022)

Clinical Outcome and Medical Cost of Originator and Generic Antihypertensive Drugs: A Population-Based Study in Yinzhou, China
por: Huang, Tao, et al.
Publicado: (2022)

Editorial: Pharmaceutical policy, impact and health outcomes
por: Kwon, Hye-Young, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jeles1uetu3br1darn8f1jfvvp